首页> 美国卫生研究院文献>Scientific Reports >Molecular Size Modulates Pharmacokinetics Biodistribution and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide
【2h】

Molecular Size Modulates Pharmacokinetics Biodistribution and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide

机译:分子大小调节药物传递生物聚合物弹性蛋白样多肽的药代动力学生物分布和肾沉积。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Elastin-like polypeptides (ELP) are engineered proteins that consist of repetitions of a five amino acid motif, and their composition is easily modified to adjust their physical properties and attach therapeutics. Because of the repetitive nature of the ELP sequence, polymer size is particularly amenable to manipulation. ELP fusion proteins are being actively developed as therapeutics for many disease applications, and how the ELP size and shape affects its pharmacokinetics and biodistribution is a critical question for the general field of ELP drug delivery. To address this, we generated a library of ELPs ranging in size from 25 kDa to 110 kDa. Terminal plasma half-life was directly proportional to polymer size, and organ biodistribution was also size dependent. The kidneys accumulated the highest levels of ELP of all sizes, followed by the liver. Within the kidney, most ELP was found in the proximal tubule, but intra-renal localization shifted from exclusively cortical to a mixture of cortical and medullary as ELP size increased.
机译:弹性蛋白样多肽(ELP)是一种工程蛋白,由五个氨基酸基序重复组成,其组成易于修饰以调节其物理性质并附着治疗剂。由于ELP序列的重复性质,聚合物尺寸特别适合操作。 ELP融合蛋白正在积极发展为许多疾病应用的治疗方法,ELP的大小和形状如何影响其药代动力学和生物分布是ELP药物递送一般领域的关键问题。为了解决这个问题,我们生成了一个ELP库,大小从25 kDa到110 kDa不等。血浆终末半衰期与聚合物大小成正比,器官的生物分布也与大小有关。肾脏累积了所有大小的最高ELP水平,其次是肝脏。在肾脏内,大多数ELP被发现在近端肾小管中,但随着ELP大小的增加,肾内定位从单纯的皮质转变为皮质和髓质的混合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号